Clinical treatment of pandrug-resistant bacterial infection consulted by clinical pharmacist  by Zhi-Wen, Yang et al.
Saudi Pharmaceutical Journal (2015) 23, 377–380King Saud University
Saudi Pharmaceutical Journal
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEClinical treatment of pandrug-resistant bacterial
infection consulted by clinical pharmacist* Corresponding author at: Department of Pharmacy, Songjiang
Hospital Afﬁliated Shanghai First People’s Hospital, Shanghai Jiao
Tong University, Zhongshan Road 746, Shanghai, China. Tel.: +86
02167720472.
E-mail address: yfyxuping@126.com (F. Wei-Jun).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.jsps.2015.01.001
1319-0164 ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Yang Zhi-Wen, Zhang Yan-Li, Yuan Man, Fang Wei-Jun *Department of Pharmacy, Songjiang Hospital Afﬁliated Shanghai First People’s Hospital, Shanghai Jiao Tong University,
Shanghai, ChinaReceived 14 October 2014; accepted 1 January 2015
Available online 10 January 2015KEYWORDS
Pandrug-resistant bacterial;
Drug therapeutic regimen;
Clinical pharmacistAbstract Objective: Pandrug-resistant (PDR) bacterial infections are associated with considerable
prolongation of hospitalization and mortality in clinical practice.
Method: This case-series study was conducted during a 3-year period from 2011 to 2013. A total
of 30 PDR patients consulted by clinical pharmacist were recorded to evaluate the anti-infection
treatment.
Results: All isolates of PDR bacteria from patients were identiﬁed as pan-drug resistant
acine-tobacter baumannii (63.3%), pan-drug resistant klebsiella pneumonia (20.0%), and pan-
drug-resistant pseudomonas aeruginosa (16.7%). Of the 30 patients, 96.7% therapeutic regimens
supposed by clinical pharmacists were applied to treat the infectious patients up to 82.8% clinical
cure rates. 30 patients completed the prescribed treatment, of which 19 underwent monotherapy
that the clinical cure rate was 78.9%, and 10 underwent combination therapy that the clinical cure
rate was 90.0%. In the following therapy, doxycycline, cefoperazone shubatan and amikacin have
the certain effect on anti-infection therapy. Combination therapy combined with doxycycline was
better treatment option for PDR infectious patients.
Conclusion: In a word, it appears to be effective for the successful therapy of PDR infections
upon tetracyclines administration.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf of King SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pandrug-resistant bacterial infection has become a signiﬁcant
public health threat as the pathogenic bacteria can be resistant
to multiple antimicrobial agents along with abuse use of broad-
spectrum antibiotics in clinical practice. As this problem con-
tinues to grow, these organisms have become resistant against
all commercially available antimicrobial agents or remain sus-
ceptible only to older, potentially more toxic agents such as
polymyxins and tigecycline, leaving limited and suboptimal
Table 1 Specimen source of PDR patients.
Specimen Cases Ratio (%)
Phlegm 17 56.7
Urine 6 20.0
Drainage liquid 4 3.3
Local secreta 2 6.7
Blood 1 3.33
Table 2 Bacterial species of PDR.
Bacteria Number of cases Constituent ratio (%)
XDRAB 19 63.3
XDRKP 6 20.0
XDRPA 5 16.7
Table 3 Clinical reception of therapeutic regimen supported
by clinical pharmacist.
Adoption Cases Ratio (%)
Full adoption 23 76.7
Adoption + Subsequent adjustment 6 20.0
Not adoption 1 3.3
378 Y. Zhi-Wen et al.options for treatment (Poulikakos et al., 2014; Matthew et al.,
2006). PDR gram-negative bacteria, namely acinetobacter bau-
mannii, pseudomonas aeruginosa and klebsiella pneumonia, is
widely spread in clinic due to their strong viability, colonization
occurrence rate and antibiotic resistance, etc.
Because PDR bacteria easily adopt resistance mechanisms,
the controversy surrounds antibiotic options with regard to the
effectiveness and susceptibility of resistant strains in clinical
practice (Corbella et al., 2000; Oliva et al., 2014). Thereby, it
is difﬁcult to deﬁne a standardized treatment regimen against
PDR bacterial infection in patients.
Our paper is a retrospective study and addresses the matter
of optimal treatment for PDR infection, focusing on 30 PDR
patients consulted by clinical pharmacist which occurred dur-
ing a 3-year period from 2011 to 2013. Interestingly, tetracy-
clines old drug doxycycline, is also applied for combination
therapeutic regimen in this study and its effectiveness is 100%.
2. Method
2.1. Patient source
This case-series study was conducted during a 3-year period
from 2011 to 2013. A total of 30 PDR patients consulted by
clinical pharmacist are recorded in detail, such as laboratory
data, diagnosis, drug use before and after consultation and
consultation summary.
The pandrug-resistant bacterials in this study are mainly
comprised of pandrug-resistant gram-negative bacillus infec-
tion, not gram-positive cocci including methicillin-resistant
staphylococcus aureus (MRSA) and vancomycin resistant
enterococcus (VRE).
2.2. Evaluation of therapeutic efﬁciency
We evaluate the therapeutic efﬁciency, according to the stan-
dard Clinical Study Guiding Principles of Antibiotics published
by Ministry of Health in 2004. The criteria are below:
Recovery: recover in symptoms, signs, laboratory examina-
tion and etiology; Improvement: get better in the patients, but
laboratory data are not fully recovered and the bacteria turns
to colonization and asymptomatic; Invalid: no improvement
or worse within 72 h after drugs administration (Dong and
Dong, 2010).
The following antibiotics were administered to the patients:
sulbactam, cefoperazone, imipenem, cystatin, meropenem,
amikacin, and doxycycline.
2.3. Data analysis
Data are presented as number (%) for categorical variables
and mean value ± standard deviation (SD) for continuous
variables. P-values < 0.05 were considered to be signiﬁcant
and all tests were two-tailed.
3. Results
3.1. Patient
The patients are consist of 21 male patients (70%) and 9
female patients (30%). Patient age is range from 43 to 90 yearswith the average age of 72 years. 17 patients (56%) have pul-
monary infection, 6 patients (20%) have urinary system infec-
tion, 3 patients (10%) have gallbladder and abdominal
infection, and 3 patients (10%) have local wound infection,
and 1 patient (3%) has blood infection (Table 1).
3.2. Bacterial distribution
Pan-drug resistant acine-tobacter baumannii, pan-drug
resistant klebsiella pneumonia and pandrug-resistant pseudo-
monas aeruginosa were isolated from patients respectively
(Table 2).
Remark: XDRAB means pan-drug resistant acine-tobacter
baumannii; XDRKP means pan-drug resistant klebsiella
pneumonia; XDRPA means pandrug-resistant pseudomonas
aeruginosa.
3.3. Therapeutic regimen and efﬁcacy outcome
In 30 patients of consultation, the clinicians recommend to
adopt 29 cases of consultation, only 1 of which is not adopted
(Table 3).
In 30 cases of drug use, 1 case is not given antibiotics and
the curative effect is improved. In 19 cases of monotherapy,
the effective rate is 78.9%, including regimen A: sulbactam
and cefoperazone 3 g q8 h ivgtt 9 cases; regimen B: imipenem
and cystatin 1 g q8 h ivgtt or meropenem 1 g q8 h ivgtt 7 cases;
regimen C: Amikacin 0.4 g qd ivgtt 3 cases. 10 cases combina-
tion therapy and the effective rate is 90.0%; regimen D: amika-
cin 0.4 g qd ivgtt + sulbactam and cefoperazone 3 g q12 h
ivgtt 5 cases; regimen E: Amikacin 0.4 g qd ivgtt + imipenem
Table 4 Therapeutic regimens and clinical efﬁcacies of patients.
Therapeutic regimen Cases Recovery Improvement Non-eﬀective Eﬀective rate (%)
Monotherapy
Regimen A 9 1 7 3
Regimen B 7 3 1 1
Regimen C 3 1 2 0
Total 19 5 10 4 78.9
Combination therapy
Regimen D 5 1 3 1
Regimen E 2 1 1 0
Regimen F 3 1 2 0
Total 10 3 6 1 90.0
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0.2 g q12 h ivgtt + sulbactam and cefoperazone 3 g q12 h ivgtt
3 cases (Table 4).
4. Discussion
Pandrug-resistant bacteria (PDR or XDR) are characterized
by the bacterial strain with sensitive to 1–2 potential active
drugs or resistant to all current antibacterial agents
(Pontikis et al., 2014). In our hospital, pandrug gram-
negative bacillus infection bacteria mainly consists of pan-
drug acinetobacter baumannii, klebsiella pneumonia and
pseudomonas aeruginosa. Pulmonary infection and urinary
system infection, as the main infection sites, are up to 80%.
30 cases were observed in this study, 15 cases of which are
sensitive to amikacin (or tobramycin) and polymyxin, and
15 cases of which are all drug resistance. Among the 30
patients, 19 patients were applied for mono-therapy with
the 78.9% effectiveness, 10 patients accepted combination
therapy with the 90.0% effectiveness, and 1 patient is not
use any antibiotic drug therapy.
In 19 cases of monotherapy regimens, 16 cases increase the
dosage and frequency of b lactam or carbapenem administra-
tion, such as cefoperazone sulbactam 3 g q8 h ivgtt, imipenem
cystatin 1 g q8 h ivgtt, meropenem 1 g q8 h ivgtt, 12 cases of
which are effective and 4 cases of which are non-effective. In
addition, 3 cases were used to the only sensitive drug (amikacin
0.4 qd ivgtt), all of which are effective. Considering the poly-
myxin is unable to obtain in our hospital, amikacin is the only
drug with higher sensitive probability among those selective
antibiotics. The results conﬁrmed that amikacin has the better
antibacterial effect in vitro and in vivo. As we known,
sulbactam and cefoperazone are not listed in the content of
sensitivity drug and its sensibility is uncertain. Thus, it was
selected empirically from clinical practice (Liang and Liang,
2011) and its usage dose increased. Interestingly, sulbactam
and cefoperazone obtain a certain therapeutic effect and their
effectiveness is about 88.9%. In a word, sulbactam still has a
certain therapeutic effect on pandrug-resistant bacteria,
especially for carbapenems resistance acinetobacter (Shiying
and Liu, 2006).
In 10 cases of combination regimens, the effective rate
reaches 90.0%. Combination regimens respectively are amika-
cin 0.4 qd ivgtt + sulbactam and cefoperazone 3 g q12 h ivgtt,
amikacin 0.4 qd ivgtt + imipenem and cystatin0.5 g q8 h ivgtt,
doxycycline 0.2 q12 h ivgtt + sulbactam and cefoperazone 3 gq12 h ivgtt. As reported in mono-therapy, sulbactam-cefope-
razone and amikacin have the obvious advantage to recovery
patients. In the following combination therapy, amikacin com-
bining with sulbactam–cefoperazone or the other antibiotics is
signiﬁcantly superior to monotherapy regimens. In addition, it
has been reported that tetracyclines, as an old drug doxycy-
cline, success in pandrug-resistant acinetobacter treatment
(Arroyo et al., 2009). In this study, tetracyclines combining
with the other antibiotics reached 100% effectiveness. The
tetracyclines administration maybe attribute to the following
reason. Tetracycline is little application in the clinical anti-
infection treatment, which led to the very low drug resistance
to pandrug-resistant acinetobacter infection. Second, the
cheap tetracyclines should be considered an alternative to tige-
cycline with very high price. In terms of drug economics and
bacterial resistance, we will pay attention to the therapeutic
effects of tetracyclines in the future and accumulate more cases
in clinical practice.
A total of 30 PDR patients consulted by clinical pharmacist
were conducted during a 3-year period from 2011 to 2013. Of
the 30 patients, 96.7% therapeutic regimens supposed by clin-
ical pharmacists were applied to treat the infectious patients up
to 82.8% clinical cure rates. Clinical pharmacists have its
professional and comprehensive advantage in medicinal prop-
erty, pharmacological action, pharmacokinetics, interaction,
untoward effect, drug efﬁcacy tracking and evaluation
(Giamarellou et al., 2013; Miyakis et al., 2011; Tsioutis
et al., 2010). Thereby, clinical pharmacists and doctors appear
to be effectively collaborative team for the successful treatment
of PDR infections.
5. Conclusion
In conclusion, doxycycline, cefoperazone shubatan and
amikacin have the certain effect on PDR infectious patients.
Combination therapy combined with doxycycline was better
treatment option.
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